Characteristics of Mel Ibr Melanoma Line Subclone after Treatment with Chicken Embryo Extract


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We continue analysis of the phenotype of human melanoma cell Mel Ibr subclone obtained previously by treatment of the parental cell line by chicken embryo extract. The present study is focused on detection of markers of epithelial-mesenchymal transition that determine enhanced metastatic and invasive potential of malignant tumors of various locations. Analysis of the expression of E-cadherin and vimentin genes in the subclone and parental cells detected activation of epithelial-mesenchymal transition in the subclone. Immunological markers CD90, CD271, and CD95 were present in the parental population, but were not detected on the subclone cells. In contrast to the parental line, cells of the analyzed subclone retain viability in serum-free medium and formed vessel-like structures characteristic of vasculogenic mimicry.

About the authors

N. M. Suraeva

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Author for correspondence.
Email: nsuraeva@yandex.ru
Russian Federation, Moscow

L. F. Morozova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

O. O. Ryabaya

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

Yu. A. Khochenkova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

A. V. Samoilov

All-Russian Research Institute of Preservation Technology

Email: nsuraeva@yandex.ru
Russian Federation, Moscow Region

O. S. Burova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

N. V. Golubtsova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

A. E. Barmashov

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow

M. A. Baryshnikova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: nsuraeva@yandex.ru
Russian Federation, Moscow


Copyright (c) 2017 Springer Science+Business Media, LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies